MHRA and NICE Launch Aligned Licensing and HTA Process to Accelerate Access to Medicines in England

Details of the Update

The new process introduces a parallel review model, enabling MHRA licensing decisions and NICE health technology assessments to occur simultaneously for new medicines. This coordinated approach is expected to reduce delays between regulatory approval and reimbursement decisions.

A key component of the initiative is the Integrated Scientific Advice service, which provides a single-entry point for pharmaceutical companies to receive coordinated guidance on regulatory requirements and evidence generation. This aims to ensure alignment between clinical development strategies and both regulatory and value assessment expectations.

The process applies specifically to pharmaceutical products seeking market entry in England, while medical devices are not included in this initial rollout. Participation will begin under an early access phase, with the first outputs expected from June 2026 for products currently in development or under review.

Stakeholders can access further details through a dedicated webinar scheduled for March 25, 2026, providing additional clarity on implementation and operational considerations.

Effective Date

The aligned MHRA-NICE process will be implemented from April 1, 2026, with initial outputs anticipated from June 2026.

Why It Matters

This update enhances regulatory efficiency by aligning licensing and reimbursement pathways, reducing duplication and improving coordination between authorities. It supports faster decision-making timelines and promotes evidence alignment across regulatory and HTA requirements, ultimately facilitating quicker patient access while maintaining robust evaluation standards.

Who This Affects

This development is relevant for Regulatory Affairs, R&D, Market Access, and Health Economics teams within pharmaceutical companies developing new medicines for the UK market, particularly those planning submissions in England under evolving regulatory and reimbursement frameworks.

Next Steps

Organizations should evaluate current product pipelines to determine eligibility for the aligned process and consider participating in the March 25 webinar to understand operational requirements. Internal submission strategies, evidence generation plans, and dossier preparation processes should be reviewed and updated to align with the integrated MHRA-NICE guidance.

As regulatory and market access pathways become increasingly interconnected, aligning strategy across both domains is essential for timely approvals and reimbursement outcomes.

RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.

FAQs

What is the MHRA-NICE aligned process?

It is a joint regulatory and HTA pathway that enables parallel review of licensing and health technology assessments for new medicines in England.

When will the new process take effect?

The process will be implemented from April 1, 2026, with first outputs expected from June 2026.

What is the Integrated Scientific Advice service?

It is a single-entry point that provides coordinated regulatory and evidence guidance to support aligned submissions to MHRA and NICE.

How can RegASK support companies under this new process?

RegASK helps organizations track regulatory and HTA developments, align evidence and submission strategies, and streamline cross-functional workflows, enabling more efficient navigation of synchronized approval pathways.